# SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

> **NCT05782192** · PHASE3 · COMPLETED · sponsor: **Shenzhen Salubris Pharmaceuticals Co., Ltd.** · enrollment: 458 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** SAL067
- **DRUG:** Alogliptin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05782192
- **Lead sponsor:** Shenzhen Salubris Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-13
- **Primary completion:** 2022-03-25
- **Final completion:** 2022-03-25
- **Target enrollment:** 458 (ACTUAL)
- **Last updated:** 2023-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05782192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05782192, "SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05782192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*